PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PTCT · as of Sep 30, 2025
Ownership Breakdown
312
Institutional Holders
▲ 16 vs Q2
$5.08B
Total Inst. Value
▲ $1.17B vs Q2
82.95M
Shares Outstanding
freeFloat 88.21%
82.76M
13F Shares Held
▲ 2.83M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PTCT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 8.29M | 10.61% | 10.61% | $508.70B | Nov 7, 2025 | ▼ 558.5K |
RTW INVESTMENTS, LP pharmaceutical preparations | 7.75M | 9.91% | 9.91% | $475.40B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 7.13M | 9.12% | 9.12% | $437.62B | Nov 12, 2025 | ▼ 349.6K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 4.92M | 6.29% | 6.29% | $301.86B | Nov 14, 2025 | ▲ 224.5K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 3.77M | 4.83% | 4.83% | $231.69B | Nov 14, 2025 | ▲ 598.5K |
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 3.28M | 4.19% | 4.19% | $201.13B | Nov 17, 2025 | ▼ 1.46M |
TORONTO DOMINION BANK pharmaceutical preparations | 3.25M | 4.15% | 4.15% | $199.24B | Nov 14, 2025 | ▲ 800.6K |
STATE STREET CORP pharmaceutical preparations | 3.13M | 4.01% | 4.01% | $192.38B | Nov 14, 2025 | ▲ 138.3K |
D. E. SHAW & CO., INC. pharmaceutical preparations | 2.17M | 2.78% | 2.78% | $133.46B | Nov 14, 2025 | ▼ 263.1K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.95M | 2.50% | 2.50% | $119.74B | Nov 12, 2025 | ▲ 16.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+7.53M shares3
New Positions
first time holders18
Decreased
−5.30M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.24M
+7.53M / −5.30M
Net new holders
+12
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PTCT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
18
Sell transactions
0.22
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Boulding Mark Elliott EXEC. VP AND CLO | May 15, 2026 | Sale | 2,356 | $72.08 | $169.8K | 105.7K | Form 4 ↗ |
Boulding Mark Elliott EXEC. VP AND CLO | May 15, 2026 | Sale | 456 | $72.67 | $33.1K | 105.2K | Form 4 ↗ |
Klein Matthew B. CHIEF EXECUTIVE OFFICER | May 13, 2026 | Award | 12,500 | — | — | 406.6K | Form 4 ↗ |
Klein Matthew B. CHIEF EXECUTIVE OFFICER | May 14, 2026 | Sale | 679 | $73.06 | $49.6K | 405.9K | Form 4 ↗ |
Klein Matthew B. CHIEF EXECUTIVE OFFICER | May 14, 2026 | Sale | 7,221 | $73.08 | $527.7K | 398.7K | Form 4 ↗ |
Klein Matthew B. CHIEF EXECUTIVE OFFICER | May 14, 2026 | Sale | 2,100 | $73.08 | $153.5K | 396.6K | Form 4 ↗ |
Klein Matthew B. CHIEF EXECUTIVE OFFICER | May 14, 2026 | Sale | 2,572 | $72.46 | $186.4K | 394.0K | Form 4 ↗ |
Boulding Mark Elliott EXEC. VP AND CLO | May 8, 2026 | Sale | 840 | $78.23 | $65.7K | 107.1K | Form 4 ↗ |
Boulding Mark Elliott EXEC. VP AND CLO | May 8, 2026 | Sale | 200 | $78.00 | $15.6K | 105.8K | Form 4 ↗ |
Boulding Mark Elliott EXEC. VP AND CLO | May 8, 2026 | Sale | 1,900 | $79.31 | $150.7K | 105.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
PTC Therapeutics, Inc. (PTCT) is primarily owned by institutional investors, who hold approximately 99.8% of total shares outstanding. Company insiders own approximately 11.79%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of PTC Therapeutics, Inc. is VANGUARD GROUP INC, holding approximately 8.29 million shares — equal to 10.61% of outstanding shares — as of September 30, 2025.
A total of 312 institutional investors currently hold PTCT stock, with a combined institutional value of approximately $5.08 billion as of the most recent 13F filing period.
Frequently asked questions
PTCT ownershipPTC Therapeutics, Inc. (PTCT) is primarily owned by institutional investors, who hold approximately 99.8% of shares. The largest shareholder is VANGUARD GROUP INC with a 10.61% stake. Company insiders hold 11.79%. Data sourced from SEC Form 13F as of September 30, 2025.